By activating GLP-1, GIP, and glucagon receptors, it exerts effects across multiple metabolic pathways, regulating appetite, energy expenditure, and glucose homeostasis, which may provide enhanced efficacy, particularly in patients with obesity and T2DM. Here, GIP is linked to type 2 diabetes mellitus.